The US Food and Drug Administration has approved a new indication for the Novartis drug Exjade (deferasirox) to treat patients aged 10 years and older who have chronic iron overload resulting from a genetic blood disorder.
Watson Pharmaceuticals Inc has agreed to pay $150 million upfront for Uteron Pharma SA, a Belgian producer of healthcare products for women. The deal also includes up to $155 million in potential future milestone payments.
Cytos Biotechnology Ltd said that it is reclaiming a vaccine asset that had been licensed to Novartis for the treatment of nicotine addiction following the failure of a Phase 2 trial. The product is a therapeutic vaccine.
Lophius Biosciences GmbH has raised nearly €4 million from existing shareholders and new shareholders to finance development of diagnostics based on T-cell technology.
Life Technologies Corp of the US has announced the acquisition of privately-owned BAC BV of the Netherlands which specialises in the development and manufacture of protein purification products. The deal will expand the US company’s capabilities in bioprocessing.
Prexton Therapeutics SA of Geneva Switzerland has negotiated an exclusive option for a series of positive allosteric modulator drugs targeting Parkinson’s disease with the goal of progressing them into clinical development. The agreement is with Domain Therapeutics SA of France.
The European Medicines Agency’s main scientific committee has turned down an application from Santhera Pharmaceuticals of Switzerland to market a drug for Leber’s Hereditary Optic Neuropathy (LHON). LHON is an inherited disease involving the progressive loss of sight.
The US Food and Drug Administration has approved a new pooled human plasma product for the treatment of patients with blood clotting disorders. The product is manufactured by Octapharma AG of Vienna, Austria.
The licensed Amgen Inc medicine Aranesp (darbepoetin alfa) failed to meet its primary endpoint in a Phase 3 trial that was investigating the drug in a new heart failure indication. There were no new safety findings identified in the study.
The European Medicines Agency is recommending the suspension of Tredaptive (laropiprant and nicotinic acid) from the European market following a study that showed the drug had insufficient clinical benefit and safety problems.